| Name | Title | Contact Details |
|---|---|---|
Kinnari Patel |
President, Head of Research & Development and Chief Operating Officer | Profile |
Chris Stevens |
Chief Operating Officer | Profile |
Chantal Petit |
VP, Chief of Staff supporting the President/Head R&D/COO at Rocket Pharmaceuticals | Profile |
Mayo Pujols |
Executive Vice President and Chief Technical Officer | Profile |
TissueTech, Inc is a Biotechnology company headquartered in Miami, FL. TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. TissueTech offers its portfolio of amniotic membrane and umbilical cord-based tissue and device products through its commercial entities: BioTissue, Inc: the industry leader in regenerative tissue therapies for ocular surface diseases and disorders. Amniox Medical: a leading technology provider to the musculoskeletal and wound care markets.
MultiPlan is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
IQuum is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Molecular Pharmacology Limited (USA) is a West Hollywood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients with autoimmune diseases.